{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:04:25Z","timestamp":1771916665074,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.msard.2025.106425","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T02:39:39Z","timestamp":1743993579000},"page":"106425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-1756","authenticated-orcid":false,"given":"Turlough","family":"Montague","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne","family":"Lichtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varitsara","family":"Mangkorntongsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuuki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Spies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106425_bib0001","article-title":"Rituximab-induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab","author":"Alahmari","year":"2019","journal-title":"Case Rep. Rheumatol."},{"issue":"6","key":"10.1016\/j.msard.2025.106425_bib0002","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.msard.2025.106425_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000961","article-title":"Improvement of comorbid psoriasis in patients with MS treated with natalizumab","volume":"8","author":"Berkovich","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106425_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211041854","article-title":"Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence","volume":"13","author":"Braun","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.msard.2025.106425_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101421","article-title":"Psoriasis in family members of patients with multiple sclerosis","volume":"36","author":"Charlton","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106425_bib0006","article-title":"Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: report of two clinical cases","volume":"35","author":"Cortese","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106425_bib0007","doi-asserted-by":"crossref","DOI":"10.5070\/D3247040917","article-title":"Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis","volume":"24","author":"Darwin","year":"2018","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.msard.2025.106425_bib0008","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2025.106425_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13943","article-title":"Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis","volume":"33","author":"Di Tullio","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2025.106425_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.msard.2025.106425_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780381112","article-title":"Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report","author":"Eibschutz","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.msard.2025.106425_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/imt-2021-0128","article-title":"Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review","volume":"14","author":"Eksin","year":"2022","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.msard.2025.106425_bib0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106425_bib0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18295\/squmj.4.2021.021","article-title":"Ixekizumab for patients with plaque psoriasis affected by multiple sclerosis: case report","volume":"21","author":"Herrera-Acosta","year":"2021","journal-title":"Sultan. Qaboos. Univ. Med. J."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13662","article-title":"Induction of psoriatic scalp and nail lesions in a patient treated with ofatumumab: a potential autoimmune dysregulation induced by anti-CD 20 therapy","volume":"30","author":"Herzum","year":"2024","journal-title":"Skin. Res. Technol."},{"issue":"4","key":"10.1016\/j.msard.2025.106425_bib0018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/imm.12219","article-title":"Distinct cytokines balance the development of regulatory T cells and interleukin-10-producing regulatory B cells","volume":"141","author":"Holan","year":"2014","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.msard.2025.106425_bib0019","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106425_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2310\/7750.2010.09063","article-title":"Psoriasis and multiple sclerosis: is there a link?","volume":"14","author":"Kwok","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000492891","article-title":"Does natalizumab induce or aggravate psoriasis? A case study and review of the literature","volume":"10","author":"Lambrianides","year":"2018","journal-title":"Case Rep. Neurol."},{"key":"10.1016\/j.msard.2025.106425_bib0022","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106425_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.09.003","article-title":"Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: a meta-analysis","volume":"18","author":"Li","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106425_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40257-018-0399-9","article-title":"Association of multiple sclerosis with psoriasis: a systematic review and meta-analysis of observational studies","volume":"20","author":"Liu","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.msard.2025.106425_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cyto.2007.09.014","article-title":"IL-17\/Th17 targeting: on the road to prevent chronic destructive arthritis?","volume":"41","author":"Lubberts","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.msard.2025.106425_bib0026","first-page":"996","article-title":"Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab","volume":"27","author":"Markatseli","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.msard.2025.106425_bib0027","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/exd.14874","article-title":"Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: a real-life experience on 638 patients with psoriasis","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.msard.2025.106425_bib0028","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2007.080929","article-title":"Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma","volume":"67","author":"Mielke","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106425_bib0029","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/s41598-021-81588-8","article-title":"Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells","volume":"11","author":"Mizumaki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106425_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106425_bib0031","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrrheum.2011.46","article-title":"Rituximab-induced changes in type 1 IFN response correlate with outcome","volume":"7","author":"Nanda","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0032","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.msard.2025.106425_bib0033","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for psoriatic arthritis: a randomized, double-blind, placebo-controlled study","volume":"31","author":"Peeters","year":"1992","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2025.106425_bib0034","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/annrheumdis-2022-eular.4211","article-title":"Emergence of spondyloarthritis following B cell-depleting monoclonal antibody therapy for multiple sclerosis","volume":"81","author":"Pham","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106425_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103832","article-title":"Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis","volume":"63","author":"Porwal","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106425_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577726","article-title":"Ixekizumab exposure associated with myelitis: a case report and a literature review","volume":"361","author":"Romozzi","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106425_bib0037","series-title":"StatPearls","article-title":"Seronegative Spondyloarthropathy","author":"Sen","year":"2023"},{"key":"10.1016\/j.msard.2025.106425_bib0038","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.msard.2025.106425_bib0039","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","article-title":"Epidemiology of spondyloarthritis","volume":"38","author":"Stolwijk","year":"2012","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"2","key":"10.1016\/j.msard.2025.106425_bib0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106425_bib0041","article-title":"Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: a case-based review","volume":"41","author":"Tsiogkas","year":"2024","journal-title":"J. Dermatol."},{"issue":"6","key":"10.1016\/j.msard.2025.106425_bib0042","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1346-8138.17143","article-title":"Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: a case-based review","volume":"51","author":"Tsiogkas","year":"2024","journal-title":"J. Dermatol."},{"issue":"17","key":"10.1016\/j.msard.2025.106425_bib0043","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.3390\/ijms21176401","article-title":"The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis","volume":"21","author":"Tsukazaki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2025.106425_bib0044","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.msard.2025.106425_bib0045","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.7150\/ijms.61973","article-title":"Role of interferon regulatory factor-mediated signaling in psoriasis","volume":"18","author":"Wang","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.msard.2025.106425_bib0046","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American college of rheumatology\/Spondylitis association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:29:03Z","timestamp":1749756543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"alternative-id":["S2211034825001671"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106425","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106425"}}